Type-specific response to neoadjuvant chemotherapy: ovarian high-grade serous carcinoma versus colorectal mucinous carcinoma

J Obstet Gynaecol Can. 2012 Jul;34(7):678-82. doi: 10.1016/s1701-2163(16)35322-1.

Abstract

Background: Ovarian carcinomas are currently managed as a single entity with no stratification for histological type. The foundation of treatment is a combination of surgery and chemotherapy. Women who are not candidates for up-front debulking surgery, either because of performance status or widespread disease, are often offered neoadjuvant chemotherapy in an effort to shrink their tumour and make resection possible.

Case: A 76-year-old woman was treated with neoadjuvant platinum-based chemotherapy for advanced ovarian cancer. At interval debulking surgery, she was found to have a concurrent mucinous colorectal carcinoma that was essentially unaffected by her treatment.

Conclusion: This case serves as an in vivo demonstration of the greater resistance to platinum-based treatments of mucinous carcinomas than of the "typical" high-grade serous ovarian cancer.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Carboplatin / administration & dosage
  • Colonic Neoplasms / pathology
  • Colonic Neoplasms / therapy*
  • Cystadenocarcinoma, Mucinous / pathology
  • Cystadenocarcinoma, Mucinous / therapy
  • Cystadenocarcinoma, Serous / pathology
  • Cystadenocarcinoma, Serous / therapy
  • Drug Resistance, Neoplasm*
  • Fatal Outcome
  • Female
  • Humans
  • Neoadjuvant Therapy*
  • Neoplasms, Multiple Primary / therapy*
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / therapy*

Substances

  • Antineoplastic Agents
  • Carboplatin